TheraVet unveils BIOCERA-VET for the U.S. companion pet health market

By Sakina Raj  | Date: 2022-07-01

TheraVet unveils BIOCERA-VET for the U.S. companion pet health market

TheraVet, a pioneer of osteoarticular disease management in pets, has reportedly rolled out its BIOCERA-VET® suite of products in the United States of America.

The BIOCERA-VET® product portfolio encompasses BIOCERA-VET® Granules, BIOCERA-VET® Osteosarcoma Ready-To-Use (RTU) and BIOCERA-VET® Bone Surgery Ready-to-Use.

Speculations have it that the U.S. companion animals health market is the largest in the world with approximately 104 million cats, 89 million dogs, and a pet ownership rate that exceeds 50%. It reportedly crossed $4.8 billion in revenue in 2021 and is predicted to witness a CAGR of 10.2% over the next eight 8 years.

Available throughout the U.S., the BIOCERA-VET line will be primarily promoted across select states – Texas, South Carolina, North Carolina, and Florida – channelizing all its marketing and commercial efforts into these four states that accommodate over 20% of the orthopaedic specialists in the U.S.

It is worth noting that the selected states showcase pet ownership rates ranging between 56% to 59%, notably useful since TheraVet’s existing partnerships with leading opinion leaders located in the Carolinas, and Texas mark a solid presence in the target areas.

The U.S. customers can now browse through BIOCERA-VET offering of synthetic bone substitutes on TheraVet’s webshop and choose from granules, bone surgery RTU, and Osteosarcoma RTU, while the BIOCERA-VET® SMARTGRAFT is scheduled to enter the U.S. market in following weeks.

Speaking of the launch, Enrico Bastianelli, CEO (Chief Executive Officer) of TheraVet, stated that the commercial launch of BIOCERA-VET® has enabled the company to foray into the largest companion market and check off one of the key goals set by the company for this year.

TheraVet is on a mission to address the current need of pet owners for innovative and curative treatments to ensure the better health of their pets.

The veterinary biotechnology company, which is listed on Euronext Growth® Paris and Brussels, works in collaboration with international opinion leaders to facilitate a more effective response to the unmet needs associated with veterinary medicine.

Source Credits:

About Author

Sakina Raj

Sakina Raj

Armed with a degree in English Literature, Sakina chose to explore the world of content writing and pursue it as a career. Sakina has been playing with words for over five years now and currently pens down articles relating to diverse domains for BonafideNews and vari...

Read More